Neuro-Oncology Expanded Gene Panel with Rearrangement, Tumor
Use
This test is useful for identifying mutations and rearrangements that may support a diagnosis or help determine prognosis for patients with central nervous system tumors. It can identify specific mutations and rearrangements within genes known to be associated with response or resistance to specific cancer therapies. The test evaluates somatic mutations within 89 genes associated with central nervous system tumors, and gene fusions within 1445 genes.
Special Instructions
A pathology report containing patient name, block number, tissue collection date, source of the tissue, and diagnosis must accompany the specimen for testing. Slide review is always performed at an additional charge when this test is ordered.
Limitations
This test cannot reliably differentiate between somatic and germline alterations. Negative results do not rule out the presence of variants below the limits of detection, with analytical sensitivity at 5% mutant allele frequency for sequence alterations and a minimum coverage of 500X for sequence. It cannot detect multi-exon deletions, duplications, or genomic copy number variants. It may not detect fusions involving non-targeted genes or deep intronic regions.
New York Approved
Methodology
NGS
Biomarkers
LOINC Codes
- 73977-1
- 50397-9
- 82939-0
- 69047-9
- 48767-8
- 31208-2
- 80398-1
- 18771-6
Result Turnaround Time
12-20 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
Submit a formalin-fixed, paraffin-embedded tissue block with an acceptable amount of tumor tissue or slides as specified. Minimum tumor area is 72 mm2.